JP2023550035A5 - - Google Patents
Info
- Publication number
- JP2023550035A5 JP2023550035A5 JP2023528148A JP2023528148A JP2023550035A5 JP 2023550035 A5 JP2023550035 A5 JP 2023550035A5 JP 2023528148 A JP2023528148 A JP 2023528148A JP 2023528148 A JP2023528148 A JP 2023528148A JP 2023550035 A5 JP2023550035 A5 JP 2023550035A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112217P | 2020-11-11 | 2020-11-11 | |
| US63/112,217 | 2020-11-11 | ||
| US202163166060P | 2021-03-25 | 2021-03-25 | |
| US63/166,060 | 2021-03-25 | ||
| PCT/US2021/058775 WO2022103834A1 (en) | 2020-11-11 | 2021-11-10 | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550035A JP2023550035A (ja) | 2023-11-30 |
| JP2023550035A5 true JP2023550035A5 (https=) | 2024-11-12 |
Family
ID=78821168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528148A Pending JP2023550035A (ja) | 2020-11-11 | 2021-11-10 | がん治療におけるｍｅｔａｐ２阻害剤及びｃｄｋ４／６阻害剤の組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230404963A1 (https=) |
| EP (1) | EP4243807A1 (https=) |
| JP (1) | JP2023550035A (https=) |
| KR (1) | KR20230117574A (https=) |
| AU (1) | AU2021378944A1 (https=) |
| CA (1) | CA3198173A1 (https=) |
| MX (1) | MX2023005501A (https=) |
| WO (1) | WO2022103834A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250127759A1 (en) * | 2021-12-02 | 2025-04-24 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer |
| CA3264343A1 (en) * | 2022-08-10 | 2024-02-15 | Syndevrx, Inc. | METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20130137831A1 (en) * | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
| CA3239447A1 (en) * | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| WO2019070755A1 (en) * | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| JP2022512826A (ja) * | 2018-10-26 | 2022-02-07 | シンデブルックス，インコーポレイティド | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 |
-
2021
- 2021-11-10 WO PCT/US2021/058775 patent/WO2022103834A1/en not_active Ceased
- 2021-11-10 AU AU2021378944A patent/AU2021378944A1/en active Pending
- 2021-11-10 US US18/036,565 patent/US20230404963A1/en active Pending
- 2021-11-10 JP JP2023528148A patent/JP2023550035A/ja active Pending
- 2021-11-10 KR KR1020237018920A patent/KR20230117574A/ko active Pending
- 2021-11-10 EP EP21819673.1A patent/EP4243807A1/en active Pending
- 2021-11-10 MX MX2023005501A patent/MX2023005501A/es unknown
- 2021-11-10 CA CA3198173A patent/CA3198173A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1011980A5 (fr) | Traitement du cancer avec des epothilones. | |
| JP2002504511A5 (https=) | ||
| JP2023550035A5 (https=) | ||
| JP7193591B2 (ja) | 化学療法の改善 | |
| JP2005506294A (ja) | テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 | |
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| JP2010043115A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| JP2021523169A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
| CN1339966A (zh) | 治疗高血压的药物 | |
| JP2024517309A (ja) | マルチキナーゼ阻害剤の医薬組成物および使用 | |
| RU2002113659A (ru) | Способ и композиции для перорального введения таксанов больным людям | |
| ES2312978T3 (es) | Potenciador del efecto antitumoral y agente antitumoral. | |
| JP2007504259A (ja) | エポチロンでの癌処置 | |
| JP2024538719A5 (https=) | ||
| EP2117539B1 (en) | A method of administering an antitumor compound | |
| JP2021533107A (ja) | 癌を治療するための併用療法 | |
| TWI813694B (zh) | 抗腫瘤劑及腫瘤治療方法 | |
| WO1996011681A1 (en) | Preventive and remedy for diarrhea | |
| JP2021516692A (ja) | 血管破壊剤およびタキサン化合物を含む癌の予防または治療用の組成物 | |
| JP2025541662A (ja) | カピバセルチブ及びベネトクラクスの治療用組み合わせ | |
| WO2023050297A1 (zh) | 一种局部药物组合物、应用及试剂盒 | |
| NL8000332A (nl) | Werkwijze voor het bereiden van een geneesmiddel dat een benzoc 1,6 naftyridine bevat. | |
| JP2023537921A5 (https=) | ||
| JP2007530567A (ja) | エポチロン及びカルボプラチンを用いる併用療法 | |
| WO2009104152A1 (en) | Combination treatment for ovarian cancer |